Cyprotex PLC, a preclinical ADME-Tox services company, will increase the size of its Watertown, Mass. facility from 4,400 sq ft to 8,200 sq ft in January 2012.

The facility expansion is driven by strong demand in North America for Cyprotex’s services and an increasing worldwide demand for the specialty in vitro toxicology services provided by the Watertown facility, in particular, Cyprotex’s CellCiphr High Content Toxicology service, the company reports.

The original facility was acquired as part of the August 2010 acquisition of Apredica.  Since that time, revenues for the facility have more than doubled. 

 “Cyprotex’s increasingly acute need to expand the Watertown facility is the consequence of a series of successful strategic efforts, including our entry into the in vitro toxicology market.  In 2011, we have continued to focus on growth, most recently with the launch of our new genomic ADME service, gADME, which allows tailored dosage regimens of drugs based on genetics.  This new service opens new commercial possibilities for compounds that historically may have had to be discontinued from development,” says
Tony Baxter, Cyprotex’s chief executive officer.

Release Date: Nov. 7, 2011
Source: Cyprotex PLC